The Diabetes Loophole Is Costing You More Than the Drug
Over 41 million Americans have no commercial insurance coverage for Wegovy, even as obesity costs the US healthcare system $173 billion annually. Insurers will pay for the heart attack but deny the drug shown to reduce cardiovascular events by 20%. This is not a cost-control strategy; it is a deferral of a bill that keeps compounding.
By Kai Brighton · 5 min read